Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sid, this transaction does not eliminate, make disappear or invalidate all the other posts regarding the positive developments that have occurred in 2015.
It's an 8K, not a company PR splash. One could sense the 8K coming given the previous PR about acquiring some related IP, although I think that PR was originally aimed at ENTB. Seems Koos, with RGBP's cash, probably used RGBP to facilitate getting the IP and then licensed to Zander since ENTB/Zander don't have the cash.
If the IP has any value in future, it will come back to benefit RGBP, just not a substantial development at this point for RGBP.
Sage, if Christine Ichim is employed full time with RGBP and is working on the cure for leukemia and other cancers, why would I want her to spend time possibly developing an application for non human use at this point.
The only credible argument would be that this "licensed IP" is actually possibly linked to the current pipeline products in a way that they see huge potential.
But if so, why not keep it as part of RGBP IP instead of giving "exclusive" rights to Zander? As I say, the only legitimate move here that I can even imagine is that this IP needs validation in animal testing first before RGBP could use in human application and having Zander do the testing keeps it in house, but with RGBP hopefully making progress on various fronts, I don't know why they wouldn't keep this IP as something for RGBP to develop and build on its own momentum.
Multiplying psuedo companies to spin shares all under the name and fist of one person, Koos, does not build investor confidence, especially with the licensing a cover for Koos to issue more shares.
Let's be real. RGBP is not going to get any cash. They are going to get a zillion shares of Zander. If ENTB is worthless at .0001-.0003, this PR is nothing more than RGBP came across some technology that they want to experiment with on animals (Does ENTB employ anyone other than Koos?) because they can't use it on humans right now.
Koos is dressing it up and selling it to himself and will issue more shares to himself in the process. These things smell and are not of the business style we need. Makes me nervous that Koos has a way of getting money for his shares that is not being reported.
I agree with Mort, this is a worthless transaction for the moment. Who works for Zander? Who is going to develop this, Koos himself?
Croc, I went back to read the PRs and 8Ks on these notes and while it is a bit confusing with the way the dates are set and then 8KAs, it appears the first shares or about 300,000 will release July 21st and several hundred thousand almost each week thereafter with about 1.5M releasing on Sept 3rd and about 3M every 30 days thereafter for a total period of 6 months.
3M shares per 22 avg trading days/month means we should anticipate up to 136,363 convertible shares being released into the market on average per day if the price has risen.
With these investors paying .028/share, almost any share price is a huge profit for them and so they can liquidate at will come August.
We can only hope that real, concrete and significant news such as the FDA approval of HemaX will accompany the release of the convertible note shares as the company will need a lot of fresh interest in buyers to keep the shares flooding into the float from driving down the price.
Sid, I wouldn't plan on it. It's more likely to settle back in .20s.
Those waiting for .10/share to buy in rather than now may only find shares in .30s and above, because while the PPS "flounders" now on little shares traded, once the plan to release news in order to drive up the price for the convertibles takes place, you won't have that chance anymore as share volume will rise drastically on the buying side before it increasing on the sell side.
AIMO
Rather quiet days. International conference in session in Sweden. I still think that given the "complexity" of the HemaX CRL GLP studies, the fact that all convertible notes were converted immediately with a 6 month delay back in Feb-Mar at .028/share, that the Koos and company plan is to build up to and submit studies so that it hits in the time frame of the first convertible shares becoming tradeable in order to maximize the profits of all those who gave money for the convertible shares. So I'm thinking Aug-Sept for submission of all HemaX data and FDA approval.
Most likely after that we will get more updates on the progress of dCellVax and any progress on the NR2F6 studies.
But I don't think they (Koos and close friend investors) want to risk releasing any significant news before then since the stock could rocket and retrace before their shares become liquid.
From now until then we will only get teasing PRs is my guess. But because we are close, the pressure to sell or the ability to sell and drive down PPS has also greatly diminished, so we await...
Best to get your fishing, swimming, sailing, golfing and the like in from now till mid August so you can spend your time watching the trading in Sept.
Now that VNDM has liquidated all the shares it needed to (we think the non registered shares of Dr. Kesari's first round of payments), there has been no significant down selling pressure or large blocks moving the price down. VNDM started at .20 and moved price all the way to .14 or lower selling off the shares. It appears for the time being we are free and clear to move back up. VNDM has been sitting at .40 for a few days.
International conference begins tomorrow. Look for some fresh money to enter over the next few days and price might migrate back to .20-.27 area, which from .14 is a nice rebound. Other than VNDM selling, I haven't noticed any large significant selling which is good news as we await news on the CRL safety studies. I'm still holding to my past expected time frame of Aug-Sept being the months of major movement. Anything before that is a bonus.
Good to see VNDM finished it's business. Now at .40 And no hidden T-trades showing after market.
Would be great to see a run start. Any sustained run over several days without a corresponding PR might mean the test results are in.
But Sid, the "current" hard facts you mention are all from the past, so you are proving my point in that you seem only focused on the past predicting the future.
I think that premise has already been proven "false" from the objective changes that have occurred in 2015. Do I say this guarantees success, no, no one can guarantee it, but the changes that are in place (cash on hand, employeed scientists, acceptance of mulitiple oral and abstract presentations at several international scientific conferences, 6 new SAB board members, possibly as a result of the research and those presentations, cooperation with established pre-clinical and clinical trial entities).
None of this would have been predicted or anticipated based on the "past actions" of any of the companies. But in fact, it now exists and every day the new patents, new discoveries, new collaborative scientists and new contracts with established scientific research centers does change the history of the company and these are the new "current" hard facts.
And it is in these current facts of 2015 that I have new hope, not blind emotional attachment.
From the UCSD Moores Cancer Center. Before 2015, who were the cooperative parties working with BMSN/RGBP? Now ask yourself in 2015, who is cooperating with RGBP?
No disrepect for Min or others, as I believe in his science, but he is involved in many projects and without being paid cash by RGBP, I don't have any idea as to his work/timeframe in the past. We do know that not one set, but 2 sets of testing was performed for HemaX that although showing efficacious effect, was not accepted by FDA for GLP reasons.
Prior to 2015, BMSN/RGBP was able to establish approved manufacturing protocol because it was working with an outside company.
Now, in 2015, HemaX is in the respected and accomplished hands of CRL and dCellVax testing is in the hands of the head of the Moore Cancer Center. Who will argue that this is not a change in direction for the better? Who will continue to argue that this is a scam (now involving CRL and Moore Cancer Center) and that it's all a smokescreen?
Sid, let's be objective and real about the comments. Kesari was brought to UCSD to head and build the dept for cancer research. Look it up and read here: The UCSD Moore Cancer Research Center
The Moore Cancer Research Center is a well respected place of research, clinical studies etc. Most likely Kesari will not personally perform the testing, but he will be responsible for the testing (i.e. setting up the protocols, assigning lab technicians etc. within the cancer research center. Obviously, Kesari, whose whole dept goals are to cure various forms of brain cancer and if you watched the short interview I posted, he states that every brain cancer is unique to the person, so he is interested in finding and validating various forms of effective treatments that can be applied to various forms of the brain cancer.
If you research the Ichims history, there is a connection with the people and UCSD Moore Cancer Center, so what I believe we are seeing is an organic expansion of cooperation of other companies and institutes (because of Ichims character, past, and scientific research) with RGBP.
I agree with you that RGBP, as Koos alone, would not be anywhere it is today, and if dependent on Koos alone, would not have much of a future. But RGBP is no longer Koos alone, the Ichims are there with their patents and IP under contract for 3 years and they are reaching out and establishing new venues of cooperation and research for the advancement of RGBP pipeline, with more to come.
The science is there and Kesari recognizes the potential, so it is a big deal that an established cancer research center's head is willing to take on the experimental proof on behalf of RGBP to submit to the FDA. As Trazbull just pointed out, it is BIG news and step forward that someone who has just been given an FDA grant is now going to do the work needed to prove to FDA the probable efficacious effect of siRNA silencing. It's not always what you know, but who you know and if Kesari is successful, the chances of the FDA denying or rejecting test data from someone they just gave a grant of 1.4 million dollars to is much lower than if the Ichims submitted it on their own. THAT IS GOOD NEWS for RGBP and it is progress from what was done in the past.
RGBP has a past, but it also has a present and a future. Let's talk about the company mainly in light of what has transpired in 2015.
Here's another link: Kesari and one brain cancer treatment
Hey, if anyone wants to know what Kesari looks and sounds like, here is a short youtube interview from a couple of years back. Kesari interview Hearing him speak on brain cancer treatments (seems he is heading up the dept at UCSD) makes this little PR statement regarding IND for dCellVax for gliomas seemingly very significant.
I like it when RGBP has deals with established names (whether corps like CRL) or people (like Kesari) that aren't for name dropping only. The fact that Kesari, who heads a neuro cancer dept at UCSD, wants to take the time to prove that dCellVax siRNA technology really works to me means that he sees real potential in the science and that bodes very well for RGBP. This isn't shares for a conf call and name dropping. This is money spent on a partnership of no less than 1 year with another established scientist to prove and be involved in RGBP's second pipeline drug and expand its treatment to brain cancer and not just breast cancer only either through a new IND or an expansion of the current IND.
Anyone here that doesn't think an approved IND for breast/brain cancer won't move PPS up, even if the cost is $200,000?
I agree. Kesari most likely wanted a deal that he was sure to be able to bank as he went along, so half (or approx 100K) of his payment in shares is liquid, so $33,000 at .15 is 220,000 shares. Unless there are other things in the works tied to shares we don't know about yet, I would expect that once VNDM has liquidated 220,000 shares or so, it might actually disappear and allow the PPS to climb.
What is good about the Kesari deal is that the second payment of $66,000 ($33K in unregistered shares) is contingent on successful experiements showing the efficacy of the siRNA gene silencing of indoleamine 2,3. That means a) Dr. Kesari believes/knows that he can produce successful testing of RGBP's IP and b) further shares issued will be after or upon public knowledge of successful testing by a well known Dr of some of RGBP's proprietary cell treatment and that dCellVax's original IND will either be expanded or a new IND will be filed for gliomas brain/spine cancer treatment.
Christine Ichim's traveling to Sweden shows that with the international SAB team, RGBP is trying to get visible on a larger scale to attract more possibilities of collaboration, licensing, and or buyout opportunities. This is all very good and its nice to see that a lot of work is being done. Just the filing of all the info in the Kesari agreement took a lot of work and shows the importance of RGBP nailing down its IP through patents.
Traz, Kfox, Meach, can anyone comment on the pros and cons of registered vs. non registered shares vis a vis yesterday's PR stating that only half of the shares issued to Kesari will be registered?
Here's explanation for form S-8. Can anyone address why only half the shares being given to Kesari are being registered and not all?
Well, it means at this point in time, the company believes it is better to save the cash on hand for "3rd party payments", such as CRL and the like, who wouldn't take cash and make agreements with those who will in shares, with obviously those contracted believing their shares may be potentially much more valuable. Basically, Kesari has agreed to be paid $200,000 in shares in return for producing experiements that "prove" the in vitro efficacy of idoleamine 2,3 silencing as stated by the 8-K.
For us, given the fact that completion of the experiments should add value to the current stock price, if $200,000 in shares issued over 3 stages with the stock price avg of .20, then the company has only diluted 1,000,000 shares and if price goes up, the share numbers go down and RGBP keeps cash on hand.
Not upset over this deal. I like the fact that at least 1/3rd of shares are contingent on the success of the experiments showing the efficacy of dCellVax as well as it appears another IND for dCellVax (or a modification/expansion of the current IND to cover more than one treatment). Hey if dCellVax gets green light for a further $200,000 expense, we will all be happy as the value will be much more.
What I need someone to explain is why are only half of the shares being registered under S-8? I don't understand why all shares would not be registered? Does that mean the registered shares are restricted in their sale for a period of time while the unrestricted can be sold immediately?
I believe one or more will be approved for clinical trials. Time and effort needed to get to approval as "drug" treatment for everyone is another issue I have not addressed. RGBP itself says their goal is to get products to and through phase 1, 2 process and then sell or spin them off. What will happen in that regard for HemaX, dCellVax and/or NR2F6 remains to be seen, but yes, I do believe HemaX from what we've been told, should get final FDA approval to move to 10 patient human clinical trials and that of itself will help put them on the map and radar of larger pharma companies.
I know why it was a mess in the past. It was a one man show with no employees other than maybe a secretary and Koos fired the other executive and gave time lines and PRs that didn't materialize.
While Koos is still at the helm, the company on paper is very different.
Why do you say companies looking at it would see a mess now?
Sid, what is your guess as to how many large investment firms are following the PRs of RGBP?
[My guess is currently few to none.]
How many large investment firms regularly research patent applications and patent approval?
[My guess is probably quite a few.]
Have you ever wondered why a stock jumps up on a good news PR, falls back and then jumps more steadily after an official SEC filing that only repeats what was issued in the company PR the previous week? I have.
[And my conclusion is that while there are lots of us and lots of DT scouring the internet for news and a quick play, larger money isn't doing that on small R&D companies. The PRs get less attention, but the SEC filings of good news and significant news will get the attention of the larger fish. The day to day price levels of RGBP are at the mercy of DT and MMs at the moment because RGBP does not have a FDA validated pipeline clinical trial. Everything is flying under the radar of most large investors and large investment firms.
The day of and all days after an official FDA approval for human clinical trials can change all that. If HemaX had been approved in 2014, I have no doubt the PPS would be higher than it is now, but with few patents and no scientists employed at the time, I don't know what attention RGBP would have gotten for the long term.
In 2015, I forget how many new patents and acquired IP RGBP has gained, but it is exponential to what it had. So when RGBP gets FDA approval for its first pipeline product and those with significantly more money take a peek at the prospects of the company, we now have much more value on paper than in 2014 for sure. 2 scientists with growing IP, 2 teams of known SAB members, each with a specific purpose related to pipeline products. 2 INDs will significant progress, patented research tools, a compelling possible cure for cancer(s) in NR2F6 stem cell differentiation. Wow - that wasn't in the books in 2014.
Why are we at the PPS we are at, I don't know and it is disappointing, but my read is because big money is not yet paying attention. Yet each conference, each oral presentation, each valid abstract, each patent successfully filed is building a much better store for big money to spend in than 2014 ever offered.
And the key to getting money in the door is 1 FDA approval for human clinical trials.
At least that's my vision and hope.
Progress.
No, it's not the rocket to the moon, but in context it means legitimate work and real IP with real patents are being built up which in the long term will add value and PPS to the company.
There are those that deny the legitimacy of the research and the scientists. Each of these filed patents are related to the work and targeted research of RGBP. One isn't for a forklift and the other for a child's toy etc. That means each application that is validated validates the research and IP of both the scientists and the company as a whole.
What if RGBP got FDA approval tomorrow for a clinical trial of a cure that while innovative, wasn't patent protected. Yes, we could all rejoice and sell our shares and then go elsewhere, since any success could be duplicated by much larger companies with much larger resources.
Instead, we don't have a rocket launch, but a much stronger and larger rocketship is quietly being built on a side launch pad while HemaX awaits its countdown.
Sid,
The comments centered around "roadblocks".
What roadblocks are you referring to in 2015?
As others have said, in the bio tech area, you don't expect to file an IND or discover a new drug and go to clinical trials in 6 months or a year. All these things take time and many trials do not even succeed.
While I agree the history of development in the past has been less than desired, 2015 has been a big improvement with full time research scientists, new lab space, actual contracting with reputed company CRL for final safety testing etc. While many company's products have failed the trials, so far we haven't encountered any scientific setback that I'm aware of, only management/communication/business dealing types of setbacks.
If HemaX doesn't pass safety testing at CRL, then we will have a big scientific setback and company roadblock, but on the other hand, if it passes, we most likely have an approved IND within 30 days of the test results being filed.
Here's my two cents for the day on today's PR.
Read the PR slowly and for what it says in the context of all that we had been informed of via PRs this year. Kesari, (brought on SAB in April along with 2 others and then on May 27 RGBP PR states filing of new IP patent regarding dendritic T cells).
After that I posted the following: Post #14018
Regarding the new divvy, no divvy, sounds like a song by golly situation. Maybe RGBP was trying to issue some bonus milestone shares and put in the wrong computer code which triggered a dispersion of shares to everyone .
Time will tell. Web chart is crazy with price fading, yet Accumulation and CMF showing strong upside. Can't figure out how that works, but hope it's true.
Just that the longer we go without any type of update or timeframe regarding CRL and the HemaX safety testing (we assume it's begun, but has it, how long, when should we expect results etc.), the more concerned I become as the memories of the past weigh on.
We need that concrete, positive news to know the company has turned the corner on the past.
Like others, how good this PR news is will most likely only be evaluated down the road. While not "bad" news, it comes with a price. Price most likely is another huge load of shares given away and further dilution of shares. For what? We don't really know. If it's for truly active involvement, then like CT said, this could ramp up the NR2F6, which in my mind has the greatest $$$ potential for the company.
If it only means they can list the scientists names on their business letterhead in return for a quarterly board meeting or a 60 minute conference call with little scientific impact, then, while it helps the Ichims gain points for the full investiture of their incentive shares, it will do little long term for the company. Let's hope the addition of these scientists truly help the Ichims pinpoint the best compounds for targeting NR2F6 cell differentiation. Any success in this area would put RGBP squarely in the news for everyone to see.
I take the news with a grain of salt since the "David Suhy" announcement to the board which was supposed to be so important is where? I think I read the fine print of a filing that David Suhy's involvement with RGBP was estimated to be about an hour per month or quarter, i.e. they bought his name only.
Let's hope these editions to the SAB are real imput additions and not letterhead additions only.
{If they were real company board members for the direction of the company, the impact on PPS would be much greater IMO}
CRL is doing the safety study on behalf of RGBP. CRL does prepare submittal for INDs, but whether RGBP has contracted with them to do so is not public info per the PRs released, and it doesn't really matter.
What we've been told via PRs is that of the HemaX IND, the FDA approved the manufacturing and even the clinical study protocols, but did not accept the safety data because it did not meet GLP standards. CRL is redoing the safety tests supposedly under approved protocols that if, positive, would "guarantee" FDA final approval as all other aspects of IND have been approved we've been told by the company.
Certainly, the data has to be submitted to the FDA for review and approval, but if it reflects previous safety test data, we know of no reason why FDA stamp of approval would not follow.
N4T, but why say this? If true, you could only know it with insider info, so sharing it here would be illegal and if you don't know it and it doesn't happen, it helps no one.
I appreciate the articles and DD you post, but let's not "cry wolf" as you know how the story ends.
Schuller, don't recall seeing the post, but no worries, don't recall seeing anything to take offense either, so consider it resolved. I too see great upside that hopefully is triggered with positive results from CRL GLP testing for HemaXellerate.
No official announcement that I recall.
The appearance of VNDM selling large quantities of shares is rarely a good sign. Hard to say what to make of it.
Next trading day will be June. Once again, I would hope June would bring us some type of update on CRL and HemaX safety test progress (We never did get any timeline or even a starting date. We are all assuming the testing was to take place immediately and I sure hope that was the case. In any event, complete or not, I would hope for some type of update on HemaX safety testing as well as some type of outlook on where dCellVax stands.
Really big news would be if they find a match for NR2F6 such that they could announce pre-clinical testing for an IND submission in that regard. With the prospect of NR2F6 being an actually cure for cancers and not just a 3, 6 or 12 month prolongation of life, that would be even bigger news than HemaX or dCellVax.
Feb 24, 2015 PR stated:
I agree on the probability of a dCellVax delayed "response" to FDA questions which might result in an altered IND or a completely new IND for dCellVax. Human clinical trials are expensive and only good for the specific IND you submit, so the fact that dCellVax will need GLP testing and the fact that hasn't yet been mentioned as part of the response, I interpret as a sign that recent developments and improvements in aspects relating to dCellVax are substantial enough that they are waiting to finish their laboratory testing to see if a "new and improved" dCellVax application with much higher chance of success can be finalized before responding to initial IND. Whether that creates a new IND or not I cannot say, but at this point I don't see the delay as a factor of incompetence or a setback, but rather because of the recent significant developments they've discovered that warrant delaying dCellVax so as to improve it significantly.
It would be my hope also that a positive relationship will develop between RGBP and CRL whereas CRL could become the main proponent of all "official" GLP studies needed for INDs. Whether or not human clinical trials take place there will depend on many different factors for which CRL might not be the best option.
Today's PR means that Ichims are making significant progress and discoveries while CRL performs the HemaX safety studies. This is indeed good news.
Here's the heart of the PR:
Finacials filed and appearing for end of March 2015. Besides the convertible share hit of 8million plus in "undervalued stock sales", I don't understand why R&D is so low and Selling, General, Administrative is so high. I guess salaries for Ichims are part of general/admin even though their entire focus is research and development.
Seems to me the result of no one pressured or in rush to sell and new buyers waiting for HemaX confirmation or other new developments, so only players left are those looking/hoping to flip, so they won't sell low knowing that there is no selling pressure to drive it lower.
200 total shares and recent daily volumes at least than $10,000 in shares traded each day. Everyone's waiting.
All's quiet. Selling volume pretty much dried up over last several days. Will catch up with everyone on release of next PR.
Let's hope so LaddyMan. We now know that HemaX is in the hands of CRL and the tests will be done according to GLP standards by a company with vast experience in how to do things right.
We also know that RGBP has developed a way of both growing and keeping MDS cell cultures needed for experiments relating to Myelodisp.... field and we know that RGBP has developed their own proprietary system for testing compounds and seeing which will be a "hit" on the NR2F6 stem cells to entice differentiation. If they find a pre-existing compound that fits the hit and is effective, then we will have a gang-buster of a pipeline product that not only might cure leukemia, but also a system of research and application that might be then applied for the discovery and cure of other types of cancer.
And we know there are full time and maybe part time scientists and lab techs working on these developments every day while CRL manages the HemaX safety tests.
Now, we wait not in darkness; we wait knowing what is happening on more than one front and we know that these things will take some time. I can wait a few weeks between PRs now knowing at least part of the current game plan and pipeline work.
That would be fine with me on two accounts, 1) the science development is what we are waiting for [CRL testing and NR2F6/NR2F2 compound hit trials do not involve or need Koos around] and 2) I don't want a PR each week unless there is something important to communicate.
With the structure in place, finances for several months and scope of IP testing underway with specific goals, we don't need a PR until there is news on the real development of one of those areas.
I, for one, would be fine with Koos sailing off and letting the testing/development proceed without interruption.